Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ969MR)

This product GTTS-WQ969MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ969MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8448MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ11550MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ3969MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ5922MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ5604MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ1501MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ6655MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ4939MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW